C. Southan, J. Sharman, H. Benson, E. Faccenda, A. Pawson et al., The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands, Nucleic Acids Research, vol.44, issue.D1, pp.1054-1068, 2016.
DOI : 10.1093/nar/gkv1037

S. Alexander, A. Davenport, E. Kelly, N. Marrion, J. Peters et al., The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors, British Journal of Pharmacology, vol.172, issue.24, pp.5744-869, 2015.
DOI : 10.1111/bph.13348

F. Montastruc, A. Palmaro, H. Bagheri, L. Schmitt, J. Montastruc et al., Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase, European Neuropsychopharmacology, vol.25, issue.10, pp.1556-65, 2015.
DOI : 10.1016/j.euroneuro.2015.07.010

L. Chebane, N. Tavassoli, H. Bagheri, and J. Montastruc, Hyperglyc??mies d???origine m??dicamenteuse : ??tude dans la Base Nationale Fran??aise de PharmacoVigilance (BNPV), Th??rapie, vol.65, issue.5, pp.447-58, 2010.
DOI : 10.2515/therapie/2010051

N. Fathallah, R. Slim, S. Larif, H. Hmouda, and S. Ben, Drug-Induced Hyperglycaemia and Diabetes, Drug Safety, vol.29, issue.12, pp.1153-68, 2015.
DOI : 10.1007/s40264-015-0339-z

G. Reynolds and S. Kirk, Metabolic side effects of antipsychotic drug treatment ??? pharmacological mechanisms, Pharmacology & Therapeutics, vol.125, issue.1, pp.169-79, 2010.
DOI : 10.1016/j.pharmthera.2009.10.010

J. Lieberman, T. Stroup, J. Mcevoy, M. Swartz, R. Rosenheck et al., Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, New England Journal of Medicine, vol.353, issue.12, pp.1209-1232, 2005.
DOI : 10.1056/NEJMoa051688

S. Stahl, What Makes an Antipsychotic Atypical?, The Journal of Clinical Psychiatry, vol.59, issue.8, pp.403-407, 1998.
DOI : 10.4088/JCP.v59n0801

T. Kenakin, Principles: Receptor theory in pharmacology, Trends in Pharmacological Sciences, vol.25, issue.4, pp.186-92, 2004.
DOI : 10.1016/j.tips.2004.02.012

M. Lindquist and . Vigibase, the WHO Global ICSR Database System: basic facts, Drug Inf J, vol.42, pp.409-428, 2008.

M. Lindquist and I. Edwards, The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center, J Rheumatol, vol.28, pp.1180-1187, 2001.

E. Brown and L. Wood, The Medical Dictionary for Regulatory Activities (MedDRA), Drug Safety, vol.20, issue.2, pp.109-126, 1999.
DOI : 10.2165/00002018-199920020-00002

M. 23-uppsala and . Centre, VigiLyze [online] Available at http://who-umc.org/DynPage.aspx? 7252&mn3=7254&mn4=7695 (last accessed 9, 2016.

H. Ayuhara, R. Takayanagi, K. Okuyama, K. Yoshimoto, T. Ozeki et al., Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists, International Journal of Clinical Oncology, vol.127, issue.Suppl5, pp.518-542, 2009.
DOI : 10.1007/s10147-009-0912-5

Y. Yamada, Y. Ohno, Y. Nakashima, M. Fukuda, R. Takayanagi et al., Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D2 receptor occupancy, Synapse, vol.4, issue.1, pp.32-39, 2002.
DOI : 10.1002/syn.10111

C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier et al., AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011, Pharmacopsychiatry, vol.44, issue.06, pp.195-235, 2011.
DOI : 10.1055/s-0031-1286287

L. Brunton, B. Chabner, and B. Knollman, Goodman and Gilman's The Pharmacological Basis of Therapeutics, 2011.

B. Martindale, The Complete Drug Reference

R. Garcia-serna, O. Ursu, T. Oprea, and J. Mestres, iPHACE: integrative navigation in pharmacological space, Bioinformatics, vol.26, issue.7, pp.985-991, 2010.
DOI : 10.1093/bioinformatics/btq061

K. Rothman, S. Lanes, and S. Sacks, The reporting odds ratio and its advantages over the proportional reporting ratio, Pharmacoepidemiology and Drug Safety, vol.13, issue.8, pp.519-542, 2004.
DOI : 10.1002/pds.1001

J. Montastruc, A. Sommet, H. Bagheri, and M. Lapeyre-mestre, Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database, British Journal of Clinical Pharmacology, vol.66, issue.6, pp.905-913, 2011.
DOI : 10.1111/j.1365-2125.2011.04037.x

S. Caroff, I. Hurford, J. Lybrand, and E. Campbell, Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial, Neurologic Clinics, vol.29, issue.1, pp.127-175, 2011.
DOI : 10.1016/j.ncl.2010.10.002

D. Naber and M. Lambert, The CATIE and CUtLASS Studies in Schizophrenia, CNS Drugs, vol.192, issue.9, pp.649-59, 2009.
DOI : 10.2165/00023210-200923080-00002

A. Shirzadi and S. Ghaemi, Side Effects of Atypical Antipsychotics: Extrapyramidal Symptoms and the Metabolic Syndrome, Harvard Review of Psychiatry, vol.14, issue.3, pp.152-64, 2006.
DOI : 10.1080/10673220600748486

H. Uchida, S. Kapur, B. Mulsant, A. Graff-guerrero, B. Pollock et al., Sensitivity of Older Patients to Antipsychotic Motor Side Effects: A PET Study Examining Potential Mechanisms, The American Journal of Geriatric Psychiatry, vol.17, issue.3, pp.255-63, 2009.
DOI : 10.1097/JGP.0b013e318198776d

G. Reynolds, Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia, Acta Psychiatrica Scandinavica, vol.155, issue.s380, pp.36-40, 1994.
DOI : 10.1038/350610a0

S. Snyder, D. Greenberg, and H. Yamamura, Antischizophrenic drugs: Affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects, Journal of Psychiatric Research, vol.11, pp.58-61, 1974.
DOI : 10.1016/0022-3956(74)90078-8

D. Bruin, M. Pettersson, M. Meyboom, R. Hoes, A. Leufkens et al., Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death, European Heart Journal, vol.26, issue.6, pp.590-597, 2005.
DOI : 10.1093/eurheartj/ehi092

L. Hazell and S. Shakir, Under-Reporting of Adverse Drug Reactions, Drug Safety, vol.29, issue.1, pp.385-96, 2006.
DOI : 10.2165/00002018-200629050-00003

C. Pierfitte, B. Bégaud, R. Lagnaoui, and N. Moore, Is reporting rate a good predictor of risks associated with drugs?, British Journal of Clinical Pharmacology, vol.49, issue.3, pp.329-360, 1999.
DOI : 10.1046/j.1365-2125.1999.00881.x